Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Immunology
Volume 2012 (2012), Article ID 929318, 5 pages
http://dx.doi.org/10.1155/2012/929318
Case Report

The Efficacy of Mizoribine (Inosine Monophosphate Dehydrogenase Inhibitor) for ANCA-Associated Vasculitis with Hepatitis B Virus Carrier

1Department of Nephrology and Hypertension, Sumitomo Hospital, 5-3-20 Kitaku Nakanoshima, Osaka 530-0005, Japan
2Department of Pathology, Sumitomo Hospital, 5-3-20 Kitaku Nakanoshima, Osaka 530-0005, Japan

Received 4 November 2012; Accepted 22 November 2012

Academic Editors: M. Hummel, A. M. Mansour, M. M. Nogueras, Y. Nozaki, M. T. Perez-Gracia, A. E. Tebo, and A. Vojdani

Copyright © 2012 Jun Muratsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Turnbull and L. Harper, “Adverse effects of therapy for ANCA-associated vasculitis,” Best Practice and Research: Clinical Rheumatology, vol. 23, no. 3, pp. 391–401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Nawata, S. Soen, R. Takayanagi et al., “Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004),” Journal of Bone and Mineral Metabolism, vol. 23, no. 2, pp. 105–109, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. M. C. Park, Y. B. Park, S. Y. Jung, I. H. Chung, K. H. Choi, and S. K. Lee, “Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy,” Lupus, vol. 13, no. 8, pp. 569–574, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. J. E. Hader, L. Marzella, R. A. M. Myers, S. C. Jacobs, and M. J. Naslund, “Hyperbaric oxygen treatment for experimental cyclophosphamide-induced hemorrhagic cystitis,” Journal of Urology, vol. 149, no. 6, pp. 1617–1621, 1993. View at Google Scholar · View at Scopus
  5. A. S. F. Lok, R. H. S. Liang, E. K. W. Chiu, K. L. Wong, T. K. Chan, and D. Todd, “Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study,” Gastroenterology, vol. 100, no. 1, pp. 182–188, 1991. View at Google Scholar · View at Scopus
  6. K. Sonda, K. Takahashi, K. Tanabe et al., “Clinical pharmacokinetic study of mizoribine in renal transplantation patients,” Transplantation Proceedings, vol. 28, no. 6, pp. 3643–3648, 1996. View at Google Scholar · View at Scopus
  7. H. Ichimura and J. A. Levy, “Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus,” Virology, vol. 211, no. 2, pp. 554–560, 1995. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. J. Gong, S. De Meyer, C. Clarysse et al., “Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro,” Journal of Viral Hepatitis, vol. 6, no. 3, pp. 229–236, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Franchetti and M. Grifantini, “Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents,” Current Medicinal Chemistry, vol. 6, no. 7, pp. 599–614, 1999. View at Google Scholar · View at Scopus
  10. E. Padalko, E. Verbeken, P. Matthys, J. L. Aerts, E. De Clercq, and J. Neyts, “Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice,” BMC Microbiology, vol. 3, article 25, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. M. C. Livonesi, R. L. Moro De Sousa, and L. T. Moraes Figueiredo, “In vitro study of antiviral activity of mycophenolic acid on Brazilian orthobunyaviruses,” Intervirology, vol. 50, no. 3, pp. 204–208, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Markland, T. J. Mcquaid, J. Jain, and A. D. Kwong, “Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX- 497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 4, pp. 859–866, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Hirayama, M. Kobayashi, Y. Hashimoto et al., “Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis,” American Journal of Kidney Diseases, vol. 44, no. 1, pp. 57–63, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Nishioka, Y. Horita, M. Tadokoro et al., “Mizoribine induces remission of relapsed ANCA-associated renal vasculitis,” Nephrology Dialysis Transplantation, vol. 21, no. 4, pp. 1087–1088, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. A. L. Cheng, C. A. Hsiung, I. J. Su et al., “Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma,” Hepatology, vol. 37, no. 6, pp. 1320–1328, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. A. S. F. Lok and B. J. McMahon, “Chronic hepatitis B,” Hepatology, vol. 45, no. 2, pp. 507–539, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Yoshioka, Y. Ohashi, T. Sakai et al., “A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome,” Kidney International, vol. 58, no. 1, pp. 317–324, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Kaneko, “Mizoribine for childhood IgA nephropathy,” Nephron, vol. 83, no. 4, pp. 376–377, 1999. View at Google Scholar · View at Scopus
  19. K. Hirayama, M. Kobayashi, Y. Hashimoto et al., “Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis,” American Journal of Kidney Diseases, vol. 44, no. 1, pp. 57–63, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Kuramoto, T. Daikoku, Y. Yoshida et al., “Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir,” Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 3, pp. 816–821, 2010. View at Publisher · View at Google Scholar · View at Scopus